Checkpoint inhibition excels in all treatment lines
Checkpoint inhibition excels in all treatment li
Preface – ESMO 2018
Preface – ESMO 2018 Sanjay Popat, PhD, FRCP
Emerging survival benefits in the small-cell setting
Emerging survival benefits in the small-cell set
Even infrequent actionable drivers are important
Early-stage NSCLC: promising (neo)adjuvant appro
CNS disease does not preclude successful treatment
CNS disease does not preclude successful treatme
Innovations in the setting of rare mutations: ALK, ROS1, NTRK, NRG1
Innovations in the setting of rare mutations: AL
Exploring synergy between anti-angiogenic drugs and immunotherapy
Exploring synergy between anti-angiogenic drugs
Frontline combinations of EGFR- and angiogenesis-targeted agents
Frontline combinations of EGFR- and angiogenesis
EGFR-positive tumors: the issue of optimal therapy across several lines
EGFR-positive tumors: the issue of optimal thera
Checkpoint inhibition in non-small-cell lung cancer: expanding the range of options
Checkpoint inhibition in non-small-cell lung can
